Anti-CD133 PARs

Anti-CD133 PARs is a preclinical **PAR-T cell therapy** being developed by Tychon Biosciences for **CD133-expressing cancer stem cells in solid tumors**. The program uses the company's prosthetic antigen receptor T-cell platform, in which **chemically self-assembling nanorings** are used to decorate and redirect a patient's T cells toward tumor-associated targets without genetic engineering. In this case, the construct is designed to engage **CD133** on cancer stem cells and **CD3** on T cells to trigger tumor cell killing; published preclinical work described anti-CD133 CSAN-based approaches as part of combination strategies aimed at eradicating solid tumors while retaining an external control feature, including switch-off with trimethoprim. Based on the company pipeline, Anti-CD133 PARs remains in the **discovery/preclinical** stage.

Other names

PAR-T anti-CD133anti-CD133 PAR-Tanti-CD-133 PAR-Tanti-CD 133 PAR-Tanti-CD133 PARsanti-CD-133 PARsanti-CD 133 PARs